Monocarboxylate transporter 8 deficiency: update on clinical characteristics and treatment

Ferdy S. van Geest, Stefan Groeneweg, W. Edward Visser*

*Corresponding author for this work

Research output: Contribution to journalReview articlePopular

4 Citations (Scopus)
8 Downloads (Pure)

Abstract

Defective thyroid hormone transport due to deficiency in thyroid hormone transporter monocarboxylate transporter 8 (MCT8) results in severe neurodevelopmental delay due to cerebral hypothyroidism and in clinical negative sequelae following a chronic thyrotoxic state in peripheral tissues. The life expectancy of patients with MCT8 deficiency is severely impaired. Increased mortality is associated with lack of head control and being underweight at young age. Treatment options are available to alleviate the thyrotoxic state; particularly, treatment with the thyroid hormone analogue triiodothyroacetic acid seems a promising therapy. This review provides an overview of key clinical features and treatment options available and under development for this rare disorder.

Original languageEnglish
Pages (from-to)689-695
Number of pages7
JournalEndocrine
Volume71
Issue number3
DOIs
Publication statusPublished - 1 Mar 2021

Bibliographical note

Funding Information:
The authors acknowledge funding support by the Sherman Foundation (WEV), Eurostars (E!11337; WEV) and Erasmus MC fellowship (WEV).

Publisher Copyright:
© 2021, The Author(s).

Fingerprint

Dive into the research topics of 'Monocarboxylate transporter 8 deficiency: update on clinical characteristics and treatment'. Together they form a unique fingerprint.

Cite this